Cleveland HeartLab Receives Crystal Award for Excellence from Ohio's Edison Technology Centers

CLEVELAND, March 27, 2014 /PRNewswire/ -- Jake Orville, CEO of Cleveland HeartLab, accepted today the Crystal Award for Excellence from Ohio's Edison Technology Centers. The presentation was made by its Edison Centers Director Council during a luncheon held at the Ohio statehouse and attended by state legislators and executives from other innovative companies.

The six Edison Technology Centers located in Ohio provide a variety of product and process innovation and commercialization services to both established and early-stage technology-based businesses. Each year the Edison Centers Directors Council recognizes companies that are succeeding at bringing innovative products to market.

Winners of the Crystal Award for Excellence qualify for recognition by having collaborated with one or more of the Edison Technology Centers located in Ohio. Cleveland HeartLab was nominated by BioOhio, an Edison Technology Center based in Columbus that is focused on building and accelerating bioscience industry, research, and education in Ohio.

"This award recognizes our commitment to innovation," said Orville. "It was made possible by our company's shared dedication and commitment to bring to market scientifically proven testing that answers unmet, clinical needs in cardiovascular disease prevention."

Cleveland HeartLab is a leading provider of cardiovascular testing to thousands of the best clinicians in the United States who are focused on wellness and prevention. It offers proprietary inflammation testing and other traditional testing such as cholesterol in order to add risk insights with the goal of identifying those who might otherwise go undetected.

About Cleveland HeartLab

Cleveland HeartLab Inc. (CHL) is an advanced clinical laboratory and cardiovascular disease management company. Established in 2009, CHL offers an array of proprietary testing and analysis focused on the identification and reduction of cardiovascular inflammation. The company operates a CLIA-certified and CAP-accredited national clinical laboratory. CHL has developed prognostic tests based on unique molecular biomarkers which are used by thousands of medical practitioners for better prediction of risk beyond standard risk factors such as cholesterol testing. CHL also has an innovative research and development group that is tasked with the discovery and commercial development of next-generation cardiovascular biomarkers for utilization through the company's clinical laboratory. This valuable research-enabled pipeline of tests and testing services is part of CHL's novel intellectual property portfolio that targets large under-served markets. For more information, visit us at www.clevelandheartlab.com.

Logo - http://photos.prnewswire.com/prnh/20140205/CL59890LOGO 

SOURCE Cleveland HeartLab Inc.